CD19 and acute lymphoblastic leukemia: Adoptive transfer of autologous CD19-targeted CAR T cells was approved by the US Food and Drug Administration (FDA) as the first therapeutic approach with a genetic engineering component [82, 83] due to remarkable response rates, particularly in patients with diffuse large B cell lymphoma (DLBCL) or acute lymphoblastic leukemia (ALL) [84–90].